Last updated: February 23, 2026
What is the Drug and Its Therapeutic Use?
NDC 00173-0736 refers to Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/3.75%. It is marketed under the brand name BenzaClin. The product is used to treat moderate to severe acne vulgaris primarily in adolescent and adult populations. It combines an antibiotic (clindamycin) to reduce bacteria and an antibacterial agent (benzoyl peroxide) aimed at clearing acne lesions.
Current Market Penetration and Competitive Landscape
Market Size and Revenue
The global acne medication market was valued at approximately USD 4.0 billion in 2022. It is projected to grow at a compounded annual growth rate (CAGR) of around 4%, reaching USD 5.0 billion by 2030. Within this, topical combination products like BenzaClin occupy a significant share, estimated at USD 600–700 million in 2022.
Major Competitors
| Product Name |
Active Ingredients |
Market Share (Estimated) |
Notes |
| BenzaClin |
Clindamycin + Benzoyl Peroxide |
15–20% |
Prescribed widely for moderate acne |
| Epiduo |
Adapalene + Benzoyl Peroxide (topical retinoid) |
10–12% |
Top competitor, slightly differentiated |
| Onexton |
Clindamycin + Benzoyl Peroxide (gel) |
5–8% |
Generic formulations increasing penetration |
| Other generics and OTC products |
Various |
Remaining share |
Growing consumer preference for OTC options |
Regulatory Status
BenzaClin received FDA approval in 2000, with a subsequent reformulation approved in 2014. It remains a prescription-only medication. Over-the-counter (OTC) options for benzoyl peroxide are widely available but lack the antimicrobial clindamycin component.
Pricing Dynamics
Historical Pricing
- Brand-name BenzaClin: Typically priced between USD 250–350 for a 45g tube.
- Generic formulations (clindamycin + benzoyl peroxide): Price ranges USD 50–150 per 45g tube.
Reimbursement and Insurance Coverage
Most prescriptions are reimbursed through commercial insurance and Medicaid, with copays ranging from USD 10–30 per prescription. Generic formulations typically benefit from broader insurance coverage.
Price Trends
Over the past five years, the price for BenzaClin has remained relatively stable. The entry of generic preparations has exerted downward pressure on prices, with some generics priced at nearly 60% lower than the brand-name product.
Market Outlook and Price Projections
Short-Term (1–3 Years)
- Pricing Stability: The core product pricing will likely remain stable due to entrenched brand loyalty and insurance agreements.
- Generic Competition: Increased availability of generics will continue to suppress average prices, leading to a projected 10–15% decrease in the average transaction price for the combination product.
Long-Term (4–10 Years)
- Market Growth: Expected CAGR of 4%, driven by rising acne prevalence among adolescents and young adults.
- Patent and Formulation Changes: No pending patent expirations or formulation innovations are currently announced, maintaining steady competition.
- Potential for Price Reduction: Likely further erosion of prices due to generic proliferation and market saturation, with some estimates suggesting a 20–30% overall decline from current levels over the next decade.
Factors Influencing Price Movements
- Regulatory Changes: Increased approval of biosimilars or new formulations could impact pricing.
- Market Penetration: Growth in outpatient and teledermatology prescriptions.
- Insurance Policies: Shifts toward favoring OTC or more affordable options.
- R&D Investing: Innovations in combination therapies may alter the competitive landscape.
Key Takeaways
- NDC 00173-0736 (BenzaClin) operates in a competitive acne treatment market projected to grow modestly.
- Current prices for the brand-name product hover around USD 250–350, with generics pricing significantly lower.
- Price erosion expected from increased generic competition will likely result in a 10–30% overall decline over the next decade.
- Market growth driven by rising acne prevalence and stable demand, offset by competition and pricing pressures.
FAQs
Q1: Can the price of BenzaClin decrease significantly due to new formulations?
A1: Yes. Introduction of new formulations or biosimilars could create pricing pressure, especially if patents expire or regulatory pathways facilitate entry.
Q2: How much does generic clindamycin + benzoyl peroxide typically cost?
A2: Generics generally cost USD 50–150 per 45g tube, representing a 40–60% reduction compared to brand-name prices.
Q3: Is there potential for over-the-counter availability affecting the market?
A3: OTC benzoyl peroxide is available, but the combination with clindamycin remains prescription-only. Broad OTC access for the combination is unlikely in the near future, limiting direct price competition.
Q4: What impact does insurance coverage have on pricing?
A4: Insurance and formulary preferences significantly influence patient out-of-pocket costs, with better coverage for generics leading to lower prices.
Q5: What regulatory developments could influence market dynamics?
A5: Approvals of biosimilars or new combination therapies by FDA or other agencies can alter the competitive landscape and affect prices.
References
- MarketsandMarkets. (2022). Acne treatment market size, share and forecast.
- Drugs.com. (2022). BenzaClin prescribing information.
- IQVIA. (2022). National Prescription Audit.
- Medicare and Medicaid data. (2022). Reimbursement trends and coverage policies.
- U.S. Food and Drug Administration. (2022). List of approved acne medications.
[1] – AAA. (2022). Global acne medication market report.
[2] – FDA. (2022). Drug approval records for dermatology products.
